Join the Oncology Voice Network. Join for Free
Never Split the Difference
Medical Science Liaison tactical empathy active listening calibrated questions 7-38-55 rule

Never Split the Difference


Share This Article


Summary

In this weeks episode, Linda Traylor, VP, Head of Medical Excellence at Acceleration Point and Josh Yoder, Sr Medical Science Liaison at Aurinia, discuss the book, Never Split the Difference by Chris Voss, a MUST read for MSLs and Medical Affairs Professionals.

Learn more about…

πŸ‘‰ How to use tactical empathy and active listening
πŸ‘‰ What is mirroring and how can it be used in field medical?
πŸ‘‰ How to use labeling, also called naming
πŸ‘‰ What are calibrated questions and how can MSLs use them
πŸ‘‰ What is the 7-38-55 rule and why is it so important

Click for Source
Medical Science Liaison, tactical empathy, active listening, calibrated questions, 7-38-55 rule

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN